Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease

Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria. Subjects will not be evaluated for efficacy and safety during the expanded access.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications